Finzati - Logo
KMDA logo

Kamada Ltd.

KMDA • Drug Manufacturers - Specialty & Generic
$8.54
▲ +0.27 (+3.26%)
Current price
EarningsLatest report: Jun 30, 2026
BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.
Market Cap
$494.36M
Growth
5.2%
Cash Flow
3/5
Trend
Mostly stable
Evidence
Stable or improving margins · 11.2%Positive revenue growth · 7.8%Positive free cash flow · 0.29Reasonable earnings multiple · 20.15Manageable debt level · 0.04
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:55 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$8.54
Change3.26%
Shares Out57.89M
Market Cap$494.36M
Enterprise Value$424.23M
52W Range6.50 - 9.35
Beta0.15
P/E22.22
P/S2.58
P/B1.83
P/FCF18.67
EV/Sales2.21

Investment DNA

How strong this company looks for long-term investors

69
out of 100
Business Quality
Margins, moat, returns
74/100
Financial Strength
Debt, cash, stability
95/100
Growth Potential
Revenue and expansion
52/100
Price Attractiveness
Cheap or expensive today
78/100
Why this score▼
Stable or improving margins · 11.2%Positive revenue growth · 7.8%Positive free cash flow · 0.29Reasonable earnings multiple · 20.15Manageable debt level · 0.04Healthy liquidity · 4.07

Analyst view

Analyst sentiment and price target

KMDA
Analyst sentiment
Based on 6 analyst votes · 2026-09-05
92/100
Bullish
Bullish
5
Hold
1
Bearish
0
Price Target
2026-08-14
Low
$11.00
Mean
$13.00
Median
$13.00
High
$15.00

Company Overview

IPO: 5/31/2013
Industry: Drug Manufacturers - Specialty & Generic
P/B i: 1.83
Debt / Equity i: 0.04
Operating Margin: 14.54%
Net Margin: 11.19%
ROE i: -
ROIC: -

Financial Health

Score19 / 20
Debt / Equity: 0.04
Current Ratio: 4.07
Quick Ratio: 2.28
Status: Strong

Insider Transactions

Recent executive and insider activity

Payorski Lilach
Transaction: 08/05/2026
BUY
Change
+30,000
Price
$7.52
Filing
08/06/2026
Type
BUY
RECANATI LEON
Transaction: 08/05/2026
BUY
Change
+30,000
Price
$7.52
Filing
08/06/2026
Type
BUY
ITSHAYEK ASSAF
Transaction: 08/05/2026
BUY
Change
+30,000
Price
$7.52
Filing
08/06/2026
Type
BUY